Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [20]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN252683 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Tumor Necrosis Factor Receptor Superfamily, Member 10a (TNFRSF10A) antibody
- Antibody type
- Monoclonal
- Description
- Protein G purified
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 32A1380
- Vial size
- 0.1 mg
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors.
E2 of hepatitis C virus inhibits apoptosis.
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.
p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Evidence that the human death receptor 4 is regulated by activator protein 1.
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand.
Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF
International journal of oncology 2015 Aug;47(2):506-16
International journal of oncology 2015 Aug;47(2):506-16
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS
PloS one 2013;8(9):e75414
PloS one 2013;8(9):e75414
Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins.
Park S, Cho DH, Andera L, Suh N, Kim I
Molecular and cellular biochemistry 2013 Nov;383(1-2):39-48
Molecular and cellular biochemistry 2013 Nov;383(1-2):39-48
Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy.
Qiu F, Hu M, Tang B, Liu X, Zhuang H, Yang J, Hua ZC
Scientific reports 2013 Dec 20;3:3565
Scientific reports 2013 Dec 20;3:3565
Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.
Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Molecular cancer therapeutics 2012 Oct;11(10):2087-95
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
Jane EP, Premkumar DR, Pollack IF
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Molecular cancer therapeutics 2011 Jan;10(1):198-208
Langerhans cells and dendritic cells are cytotoxic towards HPV16 E6 and E7 expressing target cells.
Le Poole IC, ElMasri WM, Denman CJ, Kroll TM, Bommiasamy H, Lyons Eiben G, Kast WM
Cancer immunology, immunotherapy : CII 2008 Jun;57(6):789-97
Cancer immunology, immunotherapy : CII 2008 Jun;57(6):789-97
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY
Cancer research 2008 Jul 1;68(13):5335-44
Cancer research 2008 Jul 1;68(13):5335-44
Radioresponsive tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy for malignant brain tumors.
Tsurushima H, Yuan X, Dillehay LE, Leong KW
Cancer gene therapy 2007 Aug;14(8):706-16
Cancer gene therapy 2007 Aug;14(8):706-16
E2 of hepatitis C virus inhibits apoptosis.
Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, Song YL, Bartenschlager R, Jang SK
Journal of immunology (Baltimore, Md. : 1950) 2005 Dec 15;175(12):8226-35
Journal of immunology (Baltimore, Md. : 1950) 2005 Dec 15;175(12):8226-35
4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
Kroll TM, Bommiasamy H, Boissy RE, Hernandez C, Nickoloff BJ, Mestril R, Caroline Le Poole I
The Journal of investigative dermatology 2005 Apr;124(4):798-806
The Journal of investigative dermatology 2005 Apr;124(4):798-806
Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.
Ren YG, Wagner KW, Knee DA, Aza-Blanc P, Nasoff M, Deveraux QL
Molecular biology of the cell 2004 Nov;15(11):5064-74
Molecular biology of the cell 2004 Nov;15(11):5064-74
p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Liu X, Yue P, Khuri FR, Sun SY
Cancer research 2004 Aug 1;64(15):5078-83
Cancer research 2004 Aug 1;64(15):5078-83
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
Oncogene 2003 Mar 20;22(11):1653-62
Oncogene 2003 Mar 20;22(11):1653-62
Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X, Kandasamy K, Srivastava RK
Cancer research 2003 Mar 1;63(5):1059-66
Cancer research 2003 Mar 1;63(5):1059-66
Evidence that the human death receptor 4 is regulated by activator protein 1.
Guan B, Yue P, Lotan R, Sun SY
Oncogene 2002 May 9;21(20):3121-9
Oncogene 2002 May 9;21(20):3121-9
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr
Cell death and differentiation 2002 Mar;9(3):274-86
Cell death and differentiation 2002 Mar;9(3):274-86
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand.
Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL
Journal of immunology (Baltimore, Md. : 1950) 2002 Feb 15;168(4):1831-9
Journal of immunology (Baltimore, Md. : 1950) 2002 Feb 15;168(4):1831-9
Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV
Cancer research 2001 Oct 1;61(19):7179-83
Cancer research 2001 Oct 1;61(19):7179-83
Glioma cells deficient in urokinase plaminogen activator receptor expression are susceptible to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis.
Krishnamoorthy B, Darnay B, Aggarwal B, Dinh DH, Kouraklis G, Olivero WC, Gujrati M, Rao JS
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4195-201
Clinical cancer research : an official journal of the American Association for Cancer Research 2001 Dec;7(12):4195-201
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
